+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dynavax Technologies Corporation - logo

Dynavax is a clinical-stage biopharmaceutical company with multiple product candidates in development for the treatment of autoimmune and inflammatory diseases, and the treatment of cancer. The company’s lead product candidates include HEPLISAV-B, an investigational adult hepatitis B vaccine; and AZD1419, which is in Phase II clinical trial for the treatment of asthma. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.

Asthma Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Asthma Therapeutics - Global Strategic Business Report

  • Report
  • November 2024
  • 194 Pages
  • Global
From
From
Collaboration Deals in Pharmaceuticals 2019-2024 - Product Thumbnail Image

Collaboration Deals in Pharmaceuticals 2019-2024

  • Report
  • September 2024
  • 1150 Pages
  • Global
From
From
From
From
Cancer Vaccines Global Market Report 2024 - Product Thumbnail Image

Cancer Vaccines Global Market Report 2024

  • Report
  • February 2024
  • 250 Pages
  • Global
From
From
From
Sexually Transmitted Diseases (STD) Treatment Market 2024-2028 - Product Thumbnail Image

Sexually Transmitted Diseases (STD) Treatment Market 2024-2028

  • Report
  • October 2024
  • 145 Pages
  • Global
From
B-Cell Chronic Lymphocytic Leukemia - Pipeline Insight, 2024 - Product Thumbnail Image

B-Cell Chronic Lymphocytic Leukemia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
From
From
Loading Indicator